| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04056650 Details | 2021-03-12 Interventional | 4 | 57 | Caffeine Cognitive Perfo… | Low enrollment - | |||
| NCT01846182 Details | 2021-03-12 Interventional | 2 | 112 | Duloxetine Hydr… Pregabalin Gulf War Illnes… | Terminated by Funder The study was closed by the sponsor. Recruiting was very difficult and there were multiple irregularities in enrollment, data collection, and study management. The data are unreliable for interpretation. | |||
| NCT00865280 Details | 2021-03-12 Interventional | 3 | 143 | Linezolid Moxifloxacin Communicable Di… Infections Skin Diseases Skin Diseases, … Skin Diseases, … | Terminated Changes in Food and Drug Administration (FDA) criteria for the identification and enrollment of participants with complicated skin and skin structure infections as well as the primary endpoint led to administrative termination of the study. | |||
| NCT04372082 2020-002188-72 Details | 2021-03-11 Interventional | 3 | 0 | Diltiazem Hydroxychloroqu… Niclosamide Sars-CoV2 | evidence showed chloroquine is not effective against COVID-19 - | |||
| NCT00775268 Details | 2021-03-11 Interventional | 1/2 | 31 | Fluorodeoxygluc… Lymphoma | - - | |||
| NCT04239014 Details | 2021-03-10 Interventional | 2 | 0 | Olaparib Carcinoma, Ovar… Ovarian Neoplas… Ovarian Cancer | Sponsor made the decision to terminate the DUETTE study based on the interim analysis of the
VIOLETTE study (NCT03330847) investigating the combination of ceralasertib and Olaparib, where
study closure was recommended due to insufficient efficacy. - | |||
| NCT04222842 Details | 2021-03-10 Interventional | 1 | - | Vorolanib Choroidal Neova… Myopia Neovascularizat… Myopic Choroida… | Day is not required for Anticipated dates. - | |||
| NCT04057261 Details | 2021-03-10 Interventional | 3 | 0 | Liraglutide Cardiovascular … Diabetes Mellit… Diabetes Mellit… Type 2 Diabetes | A study start is currently not foreseeable for organizational reasons. Due to the delays,
research has also been focused on new compounds, which has reduced the interest in the
potential results of the above-mentioned clinical trial. - | |||
| NCT01127893 Details | 2021-03-10 Interventional | 3 | 1 | Tanezumab Osteoarthritis | See termination reason in detailed description. Due to the US FDA imposed clinical hold, enrollment and further dosing with study medication was stopped prematurely, only 1 participant was enrolled and the study was terminated early. Designation of outcomes as primary, secondary based on study team input as study did not specify them as primary or secondary. | |||
| NCT03661983 2018-002270-48 Details | 2021-03-09 Interventional | 4 | 36 | Aripiprazole Tourette Syndro… Tourette's Diso… | Lack of feasibility for completion of the trial within a reasonable time frame. This trial was terminated early due to the withdrawal of post-marketing commitment (PMC) to FDA. The planned interim analysis was not conducted either. | |||
| NCT01206296 Details | 2021-03-09 Interventional | 2 | 9 | Gemcitabine Adenocarcinoma Pancreatic Aden… | Study suspended - | |||
| NCT03258476 Details | 2021-03-08 Interventional | 4 | 0 | Guanfacine Stress Disorder… Stress Disorder | Contract terminated - | |||
| NCT04374279 Details | 2021-03-05 Interventional | 2 | 0 | Bicalutamide COVID-19 SARS-CoV 2 | Limited resources. - | |||
| NCT03600467 Details | 2021-03-05 Interventional | 2 | 4 | Seviteronel Androgen Recept… Solid Tumor | Sponsor - | |||
| NCT03198221 Details | 2021-03-04 Interventional | 4 | 14 | Citric Acid Magnesium Oxide Picosulfate sod… Polyethylene gl… Bowel Preparati… | Low enrollment due to difficult eligibility criteria and participant prep logistics - | |||
| NCT04543916 Details | 2021-03-03 Interventional | 1/2 | 0 | Irinotecan Venetoclax Lung Neoplasms Small Cell Lung… Refractory Smal… Relapsed Small … | AbbVie decided to stop trial involving Venetoclax for safety measures needed - | |||
| NCT02796144 Details | 2021-03-03 Interventional | 4 | 71 | Metformin Overweight Psychotic Disor… Schizophrenia Weight Loss Schizoaffective… | The FDA advised of a possible health risk associated with lorcaserin and the drug is being
withdrawn. - | |||
| NCT02340156 Details | 2021-03-03 Interventional | 2 | 1 | Temozolomide Glioblastoma Recurrence RECURRENT GLIOB… | - The number of participant was too small for statistical analysis. The study was terminated. | |||
| NCT00748566 Details | 2021-03-03 Interventional | 4 | 172 | Ziprasidone Mental Disorder… Metabolic Syndr… Psychotic Disor… Schizophrenia Schizophrenia S… Schizophrenia a… | See Detailed Description The study was prematurely terminated by sponsor due to changes in organizational strategy and resources, not due to safety concerns. | |||
| NCT00359151 Details | 2021-03-03 Interventional | 4 | 22 | Celecoxib Osteoarthritis Pain | This study was terminated early due to slow enrollment. - |